Phase II study of doxorubicin and mitomycin in non-small cell bronchogenic carcinoma.

Thirty patients with advanced measurable non-small cell bronchogenic carcinoma were treated with a combination of doxorubicin (50 mg/m2 every 3 weeks) and mitomycin (20 mg/m2 every 6 weeks). One complete and three partial responses were observed. This response rate is similar to that reported for either drug used alone.